Birds and humans have different types of receptors in their respiratory tract that flu viruses attach to, like a lock ...
Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...
Key targets of the programme are elderly people and children. This programme is a part of Sanofi's commitment to improving ...
Sanofi is ending a Phase 2 clinical trial that’s testing a drug from Denali for multiple sclerosis, putting a stop to the development plan. … ...
This dashboard provides a weekly overview of key trends on the activity of respiratory viruses, such as influenza (flu), COVID-19 and respiratory syncytial virus (RSV) in Canada. Historical reports ...
The FDA has approved updated labeling for Flublok (influenza vaccine) to include new safety data involving pregnant individuals.
Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...
Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...
High-dose flu vaccinations resulted in a 23% reduction in hospitalizations among people aged 65 years or older, according to ...
Odile Launay reported conflicts of interest with Sanofi, MSD, Pfizer, GSK, and Moderna.How the End of the COVID Public Health Emergency May Affect YouCDC Makes Public Influenza A Wastewater Data to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback